Published in J Thorac Dis on May 01, 2014
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | NCT01829971
Translational research in thoracic surgery-the National Taiwan University Hospital experience. J Thorac Dis (2016) 0.75
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
The new World Health Organization classification of lung tumours. Eur Respir J (2001) 6.91
Cancer-susceptibility genes. Gatekeepers and caretakers. Nature (1997) 5.87
MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell (2008) 5.34
Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc Natl Acad Sci U S A (2008) 4.75
Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet (2011) 4.26
The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol (2008) 3.63
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med (2012) 3.52
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet (2011) 3.41
Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol (2014) 2.57
MicroRNAs and the hallmarks of cancer. Oncogene (2006) 2.55
Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell (2010) 2.38
BAP1 and cancer. Nat Rev Cancer (2013) 2.23
MicroRNA in lung cancer. Br J Cancer (2010) 1.97
p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene (2011) 1.86
The pathogenesis of mesothelioma. Semin Oncol (2002) 1.80
High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A (1995) 1.76
Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res (1995) 1.67
Merlin is a potent inhibitor of glioma growth. Cancer Res (2008) 1.47
Molecular biology of lung cancer: clinical implications. Clin Chest Med (2011) 1.47
Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. Clin Cancer Res (2011) 1.35
Tumours associated with BAP1 mutations. Pathology (2013) 1.35
Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev (2010) 1.24
Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene (1995) 1.24
Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer (2008) 1.22
Recent advances in non-small cell lung cancer biology and clinical management. Discov Med (2012) 1.20
Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer (1997) 1.19
Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci (2009) 1.13
A view from above. Eur J Cardiothorac Surg (2009) 1.09
MicroRNA in lung cancer diagnostics and treatment. Mutat Res (2011) 1.09
Hypothesis-generating research and predictive medicine. Genome Res (2013) 1.08
Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. Clin Cancer Res (1999) 1.03
Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer (1999) 1.00
Clinical statement on the role of the surgeon and surgical issues relating to computed tomography screening programs for lung cancer. Ann Thorac Surg (2013) 0.98
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung Cancer (2014) 0.97
Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis. Front Med (2013) 0.97
Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene. Int J Cancer (1998) 0.93
Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer (2002) 0.93
Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch Pathol Lab Med (2012) 0.91
PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg (2008) 0.89
Unbalanced translocation, a major chromosome alteration causing loss of heterozygosity in human lung cancer. Oncogene (2008) 0.89
Molecular biology or ultrastructural biology? Nature (1961) 0.87
The role of epigenetics in malignant pleural mesothelioma. Lung Cancer (2013) 0.87
The surgeon's role in molecular biology. J Thorac Cardiovasc Surg (2012) 0.86
The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer (2003) 0.86
Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer (2005) 0.81
Allelic imbalance in 1p, 7q, 9p, 11p, 12q and 16q regions in non-small cell lung carcinoma and its clinical association: a pilot study. Mol Biol Rep (2013) 0.80